ImmuPharma (LON:IMM) Issues Earnings Results

Share on StockTwits

ImmuPharma (LON:IMM) issued its quarterly earnings data on Wednesday. The company reported GBX (1.69) (($0.02)) earnings per share (EPS) for the quarter, Digital Look Earnings reports.

Shares of IMM stock opened at GBX 11.48 ($0.15) on Thursday. ImmuPharma has a 1 year low of GBX 6.91 ($0.09) and a 1 year high of GBX 32.29 ($0.42). The company has a debt-to-equity ratio of 0.51, a current ratio of 6.73 and a quick ratio of 3.90. The stock’s 50 day simple moving average is GBX 13.41 and its two-hundred day simple moving average is GBX 13.33. The company has a market cap of $28.26 million and a PE ratio of -2.87.

ImmuPharma Company Profile

ImmuPharma plc, a pharmaceutical company, develops drug candidates based on peptide therapeutics to treat serious medical conditions. The company's lead product candidate is the Lupuzor, which has completed Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.

Read More: Reverse Stock Split

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Grand Canyon Education  Stock Rating Lowered by TheStreet
Grand Canyon Education Stock Rating Lowered by TheStreet
BG Staffing  versus The Competition Head to Head Survey
BG Staffing versus The Competition Head to Head Survey
Head to Head Review: BG Staffing  versus Its Rivals
Head to Head Review: BG Staffing versus Its Rivals
ImmuPharma  Issues  Earnings Results
ImmuPharma Issues Earnings Results
Hamilton Beach Brands  Upgraded to B- by TheStreet
Hamilton Beach Brands Upgraded to B- by TheStreet
LendingClub Corp  Insider Valerie Kay Sells 6,439 Shares of Stock
LendingClub Corp Insider Valerie Kay Sells 6,439 Shares of Stock


 
© 2006-2020 Zolmax.